Contineum Therapeutics (CTNM)
Discovers and develops oral small-molecule therapies for neuroscience, inflammation and immunology.
Something off on this page? Send us feedback.
Develops oral small-molecule therapies for neuroscience, inflammation and immunology indications. Its clinical and discovery portfolio includes PIPE-791, PIPE-307 and CTX-343, with PIPE-307 subject to a global license arrangement with Janssen.
Discovers and develops oral small-molecule therapies for neuroscience, inflammation and immunology indications. The portfolio comprises clinical candidates PIPE-791, PIPE-307 and CTX-343, alongside discovery programs, within a single reportable segment.
Operations are concentrated in San Diego, while the company pursues programs for patients globally. PIPE-307 is covered by an exclusive worldwide license to Janssen; Contineum retained the right to advance it in a Phase 2 trial for relapsing-remitting multiple sclerosis.
The VISTA trial did not meet its prespecified efficacy endpoints, and Janssen has sole discretion over further PIPE-307 development for relapsing-remitting multiple sclerosis.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Reiterate | Equal Weight | $14 | $16 | |
| Jan 8, 2026 | Morgan Stanley | Downgrade | Overweight | Equal Weight | $14 | |
| Nov 24, 2025 | Robert W. Baird | Target | $16 | $14 | ||
| Nov 21, 2025 | RBC Capital | Reiterate | Outperform | $30 | $22 | |
| Sep 25, 2025 | Leerink Partners | Target | $20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $236.6M · Total debt $6.6M · Total assets $250.4M · Shareholders' equity $239.7M
- Revenue
- $0
- Operating income
- −$17.4M
- Net income
- −$15.2M
No dividends on record.
| Institutions91 holders · as of Mar 31, 2026 | 81.22% | 30.56M shares | |
| Insiders3 holders · as of Aug 3, 2026 | 0.44% | 166.0K shares | |
| Otherremainder | 18.34% | 6.90M shares |
37.62M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Suvretta Capital Management, LLCInstitution | 7.55% | 2.84M A | 13Fas of Mar 31, 2026 |
Janus Henderson Group PLCInstitution | 7.27% | 2.73M A | 13Fas of Mar 31, 2026 |
Johnson & JohnsonInstitution | 5.26% | 1.98M A | 13Fas of Mar 31, 2026 |
Franklin Resources IncInstitution | 4.89% | 1.84M A | 13Fas of Mar 31, 2026 |
Balyasny Asset Management L.P.Institution | 4.48% | 1.69M A | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Carmine N. Stengone | director, officer: CEO and President | −2,500 | $16.01 |
| Jul 9, 2026 | Daniel S. Lorrain | officer: Chief Scientific Officer | −25 | $16.00 |
| Jul 8, 2026 | Carmine N. Stengone | director, officer: CEO and President | −2,500 | $16.00 |
| Jul 1, 2026 | Daniel S. Lorrain | officer: Chief Scientific Officer | −8,353 | $15.84 |
| Jun 30, 2026 | Daniel S. Lorrain | officer: Chief Scientific Officer | −28,826 | $16.04 |
- Bristol-Myers Squibb
Phase 3 LPA1 antagonist developer in IPF
- MannKind
Inhaled nintedanib developer in Phase 2 IPF testing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Contineum Therapeutics | $17.24 | +4.14% | $648.6M | — | — | — | — |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| MannKind | $3.99 | −1.12% | $1.29B | — | — | 3.3 | +42.9% |
| Median | 14.9 | 10.6 | 3.0 | +24.3% |